Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia. by Raguenaud, M-E et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Pediatrics
Open Access Research article
Excellent outcomes among HIV+ children on ART, but 
unacceptably high pre-ART mortality and losses to follow-up: a 
cohort study from Cambodia
Marie-Eve Raguenaud*1, Petros Isaakidis1, Rony Zachariah2, Vantha Te3, 
Seithabot Soeung4, Kazumi Akao4 and Varun Kumar4
Address: 1Médecins Sans Frontières, 72, Street 592, Phnom Penh, Cambodia, 2Médecins Sans Frontières, Operational Research Unit, 94 rue Dupre, 
1090 Brussels, Belgium, 3Pediatric Department, Donkeo Referral Hospital, Takeo, Cambodia and 4Angkor Hospital for Children, Siem Reap, 
Cambodia
Email: Marie-Eve Raguenaud* - eve_raguenaud@hotmail.com; Petros Isaakidis - petrosisaakidis@yahoo.com; 
Rony Zachariah - rony.zacharia@brussels.msf.org; Vantha Te - cdc_takeo@camintel.com; Seithabot Soeung - varun@angkorhospital.org; 
Kazumi Akao - kazumiakao0520@hotmail.com; Varun Kumar - varun@angkorhospital.org
* Corresponding author    
Abstract
Background: Although HIV program evaluations focusing on mortality on ART provide important
evidence on treatment effectiveness, they do not asses overall HIV program performance because
they exclude patients who are eligible but not started on ART for whatever reason. The objective
of this study was to measure mortality that occurs both pre-ART and during ART among HIV-
positive children enrolled in two HIV-programs in Cambodia.
Methods: Retrospective cohort study on 1168 HIV-positive children <15 years old registered in
two HIV-programs over a four-year period. Mortality rates were calculated for both children on
treatment and children not started on ART.
Results: Over half (53%) of children were 5 years or above and only 69(6%) were <18 months.
Overall, 9% (105/1168) of children died since the set-up of the programs. By the end of the
observation period, 66(14.5%) patients not on ART had died compared to 39(5.5%) of those under
treatment, and 100(22%) who did not start ART were lost-to-follow-up compared to13(2%) on
ART. 66/105 (62.8%) of all in-program deaths occurred before starting ART, of which 56% (37/66)
and 79% (52/66) occurred within 3 and 6 months of enrolment respectively. Mortality rate ratio
between children not on ART and children on ART was 4.1 (95%CI: 2.7–6.2) (P < 0.001). The most
common contributing cause of death in first 3 months of treatment and in first 3 months of program
enrollment was tuberculosis. 41/52 (79%) children who died within 6 months of enrollment had
met the ART eligibility criteria before death.
Conclusion: HIV-positive children experienced a high mortality and loss-to-follow-up rates before
starting ART. These program outcomes may be improved by a more timely ART initiation.
Measuring overall in-program mortality as opposed to only mortality on ART is recommended in
order to more accurately evaluate pediatric HIV-programs performance.
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Background
Anti-retroviral treatment (ART) significantly decreases
mortality and pediatric HIV care programs in resource-
limited settings achieve treatment outcomes similar to
those in industrialized countries [1-5]. The success of
pediatric HIV/AIDS care programs has been generally
assessed by measuring the response of children placed on
ART. Although such program evaluations provide impor-
tant evidence on treatment effectiveness, they do not cor-
rectly assess overall HIV program performance as the
cohort that is assessed excludes individuals who are eligi-
ble but not started on ART for whatever reason.
Thus the current "snapshot" is restrictive and little is
known about deaths occurring prior to ART initiation
(pre-ART mortality), which go unreported.
Information on such "hidden mortality" from program-
matic settings could bring a better understanding on this
issue and help identify ways to optimize monitoring and
assessments of overall performance of pediatric HIV/AIDS
programs.
In the past five years the Ministry of Health, Médecins
Sans Frontières (MSF), and Angkor Hospital for Children
(AHC) have been supporting pediatric HIV/AIDS care
programs in Takeo and Siem Reap provinces in Cambo-
dia. Overall, excellent clinical, immunological and viro-
logical outcomes under ART were achieved in these two
pediatric cohorts [2].
We conducted a retrospective analysis of program data in
order to measure mortality occurring both before (pre-
ART) and during ART among HIV-positive children
enrolled for HIV/AIDS care in two hospitals in Cambodia.
Methods
Study setting and population
The study was conducted in the pediatric HIV clinics of
the Angkor Hospital for Children (AHC) a charity hospi-
tal located in Siem Reap province (population 700 000),
and in Donkeo Referral Hospital, a public facility in Takeo
province (population 800 000). The majority of the pop-
ulation live in rural areas and their socioeconomic status
is very low. All children <15 years of age with confirmed
HIV-positive status registered in these two HIV programs
from January 2003 until December 31 2007 were
included in the study. Children switched at any time to
second line therapy were also included in the analysis.
The HIV clinics are located within the hospital and oper-
ate on an out-patient basis, providing doctor-based clini-
cal care and follow-up by a multi-disciplinary team
including counselors, drug-educators and nurses. Most
patients are self-referred or referred by private or public
health facilities in the province. In both study locations a
prevention of mother to child transmission (PMTCT) pro-
gram was in place albeit with limited coverage. On aver-
age, one fifth of children enrolled in the program in Takeo
entered through the PMTCT program (no data available
for Siem Reap location). Virological testing (detection of
plasma HIV-1 RNA by RT PCR) for HIV diagnosis in chil-
dren younger than 18 months of age was made available
during the year 2006. Prior to that time, children were
identified as having presumptive HIV infection on the
basis of clinical signs and symptoms, with diagnosis con-
firmed by antibody testing at 18 months.
The patient assessment at first consultation included a his-
tory and physical examination as well as determination of
clinical disease stage using CDC clinical categories [6]
(from 2003–early 2006) and WHO criteria (2006–2007)
[7,8]. If the patient was in an advanced stage of disease
(WHO 3 or 4, CDC "C"), s/he was followed up on a
monthly basis or more frequently if this was merited by
clinical status. If the patient was in WHO stage 1 or 2 or
CDC stage A or B, appointments were given on two
monthly basis. Blood sampling was generally performed
on admission (or upon confirmation of HIV status) for
CD4 count or percentage measurement and every 6
months thereafter. Average delay in obtaining CD4 results
was one to three weeks. In the early years of the program
the protocol recommended to repeat CD4 a second time
after 1–3 months in order to confirm a low CD4 value
before starting ART.
At each visit a standardized admission or follow up sheet
was filled in by the doctor.
An active tracing system for patients who failed to attend
a clinic appointment was set-up, and included home visits
and additional counseling sessions. Due to limited
resources, such defaulter tracing system was reserved
mainly for children who were initiated on ART.
ART eligibility, regimens and treatment outcomes
Criteria to start ART in HIV-positive children were: WHO
stage 3/4 or CDC stage C or CD4 < 200 cells/mm3 (for
individual ≥ 5 years of age) or CD4% < 20.0% in Siem
Reap (for individuals < 5 years of age) or CD4% < 15.0%
in Takeo (for < 5 years of age). As of 2006 protocols were
standardized for both locations and the new WHO criteria
were used (CD4 < 200 cells/mm3 for children ≥ 5 years,
CD4% < 15% for children 36–59 months, and CD4% <
20% for children 12–35 months) [8]. According to the
same clinical and immunological criteria, children were
offered fluconazole and cotrimoxazole prophylaxis, pro-
vided there were no contraindications.BMC Pediatrics 2009, 9:54 http://www.biomedcentral.com/1471-2431/9/54
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In one clinic at the beginning of the program a maximum
of five children per month were started on ART due to lim-
ited capacity for follow-up, creating a backlog of patients.
The majority of patients were started on a standard first-
line regimen of stavudine, lamivudine and nevirapine.
Zidovudine and efavirenz were used as alternatives in case
of intolerance or interaction with other drugs. Patients
and caregivers received at least three ART-preparation
counseling sessions, one week apart, before starting treat-
ment. Potential reasons for deferral of treatment included
active opportunistic infection(s), lack of caregiver readi-
ness or a failure to attend consecutive follow-up appoint-
ments indicating potentially problematic adherence to
treatment.
Outcomes were standardized and included: alive and on
active follow-up, died, transferred out, and lost-to-follow-
up (>3 months) (LTFU). Most transfers took place after
2005 as new pediatric HIV clinics started operating in the
country. All medical services were offered free of charge
for HIV-positive children and additional support was pro-
vided by various Non-Governmental Organizations
(NGOs) including transportation, accommodation and
food allowance.
Data management and statistical analysis
Information from structured patient files, admission and
follow up sheets, were entered routinely by data clerks
into a HIV-specific database (FUCHIA 1.6.0 developed by
EPICENTRE, Paris, France. (available at http://www.epi
centre.msf.org/tools/fuchia1). Data entry was cross-
checked and updated from patient files.
To accommodate for the fact that immunological criteria
for severe HIV immunodeficiency were age-specific, we
created a categorical variable describing the presence of
severe immunodeficiency according to the WHO 2006 cri-
teria (18–35 months: <20% CD4% or <750 CD4 count;
36–59 months: <15% CD4% or <350 CD4 count; ≥ 59
months: <15% CD4% or <200 CD4 count). As both the
CDC clinical staging system and the WHO staging system
were used by the programs, WHO stages 3 and 4 were
grouped together with CDC grade C as an indicator of
advanced AIDS disease. Date of ART eligibility was calcu-
lated for each patient using the CD4-based ART initiation
criteria and information from the patient file. The most
likely attributable cause of death of each patient was
assigned based on the last diagnosis available in patient
records.
Person-time analysis was used for the mortality rate. The
observation period went up to April 2008 when the data
set was censored. We provided the outcomes at 1 year after
enrollment. Data analysis was performed using STATA 8.2
software (Stata Corporation, College Station, Texas, USA).
As this was a retrospective study using program data,
informed consent from individual patients was not
obtained. The study protocol was approved by the Ethics
Review Board of Médecins Sans Frontières and by the
Institutional Review Board of Angkor Hospital for Chil-
dren.
Results
Enrolment, follow up and main outcomes
1168 HIV-positive children were registered in the two HIV
clinics between January 2003 and December 2007, and
included in the analysis. Over half (53%) of children were
5 years or above and only 69 (6%) were less than 18
months. 148 (27%) children ≥ 5 years had first CD4 lym-
phocyte count < 50 cell/μl (data available for 87% of chil-
dren). 164 (41%) children aged 18–59 months had first
CD4 lymphocyte percentage < 15% (data available for
88% of children). The characteristics of patients at time of
registration are shown in Table 1.
During the study period, 714 (61%) children started ART.
The median period of observation for patients not receiv-
ing ART was 11 months (IQR 2.4–25). Among the 454
patients who did not start ART, 66 (14.5%) had died, 100
(22%) were lost-to-follow-up, 40(9%) were transferred
out, and 248 (55%) were still enrolled in the program and
on active follow-up.
For children who started ART, the median interval
between registration and ART initiation was 4.7 months
(IQR 2.5–8.8). The median period of observation under
treatment was 2 years (IQR 0.9–3.0). By the end of the
observation period 39 (5.5%) patients under treatment
had died, 13 (2%) were lost-to-follow-up, 61 (8.5%) were
transferred to other programs, and 601 (84.2%) were still
alive and on follow up.
The main outcomes of children who started ART and
those who never started ART after 1 year of enrollment in
the HIV care program are shown in Figure 1 and Figure 2.
27/248 (11%) of children alive at the end of the observa-
tion period were actually eligible for treatment.
Mortality
Overall, 9% (105/1168) of children died from the begin-
ning of the program. Overall in-program mortality rate
was 4.27 deaths per100 person-year (95%CI: 3.5–5.2).
66/105 (62.8%) of all in-program deaths occurred before
starting ART, of which 56% (37/66) occurred within 3
months of enrollment, and 23% (15/66) between 3 and 6
months after enrollment. Table 2 shows the mortality
rates for children who received treatment by measuringBMC Pediatrics 2009, 9:54 http://www.biomedcentral.com/1471-2431/9/54
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Table 1: Characteristics of children enrolled in the HIV programs at the time of registration and their outcomes.
<18 months 18–59 months ≥ 60 months Total
Number of children registered 69 (5.9%) 479 (41.0%) 620 (53.1%) 1168
Gender
Female 33 (47.8%) 230 (48.0%) 292 (47.1%) 555 (47.5%)
WHO or CDC stage
WHO 1/2 or CDC stage N/A/B 34 (50.0%) 310 (64.7%) 395 (63.7%) 739 (63.3%)
WHO 3/4 or CDC C 34 (50.0%)
(n = 68)
169 (35.3%) 225 (36.3%) 428 (36.7%)
(n = 1167)
CD4 cells/mm3, median (IQR) 753 (338–1280)
(n = 40)
643 (310–1049)
(n = 353)
245 (40–599)
(n = 561)
410 (94–818)
(n = 954)
CD4 cells/mm3
<50 2 (5.0%) 22 (6.2%) 149 (26.6%) 173 (18.1%)
50–350 8 (20.0%) 75 (21.3%) 175 (31.2%) 258 (27.0%)
>350 30 (75.0%) 256 (72.5%) 237 (42.2%) 523 (54.8%)
CD4%, median (IQR) 18.71(12.44–23.75)
(n = 48)
18 (10–24.8)
(n = 415)
9.41 (2.76–18.72)
(n = 399)
14.47 (5.33–23)
(n = 862)
CD4% group3
<15.0% 16 (33.3%) 164 (39.5%) 260 (65.2%) 440 (51.0%)
15–24.9% 21 (43.7%) 148 (35.7%) 81 (20.3%) 250 (29.0%)
≥ 25.0% 11 (22.9%) 103 (24.8%) 58 (14.5%) 172 (20.0%)
Weight for height*
≥ -2 z-score 33 (55.0%) 366 (81.0%) 435 (76.7%) 834 (77.3%)
<-2 and ≥ -3 z-score 12 (20.0%) 53 (11.7%) 82 (14.5%) 147 (13.6%)
<-3 z-score 15 (25.0%) 33 (7.3%) 50 (8.8%) 98 (9.1%)
Weight for age
≥ -2 z-score 29 (42%) 153 (31.9%) 127 (20.5%) 309 (26.5%)
<-2 and ≥ -3 z-score 12 (17.4%) 176 (36.7%) 287 (46.4%) 475 (40.7%)
<-3 z-score 28 (40.6%) 150 (31%) 205 (33.1%) 383 (32.8%)
Year of admission
2003 2 (2.9%) 53 (11.1%) 36 (5.8%) 91 (7.8%)
2004 13 (18.8%) 117 (24.4%) 183 (29.5%) 313 (26.8%)
2005 17 (24.6%) 123 (25.7%) 165 (26.6%) 305 (26.1%)
2006 19 (27.5%) 109 (22.8%) 130 (21.0%) 258 (22.1%)
2007 18 (26.1%) 77 (16.1%) 106 (17.1%) 201 (17.2%)
Started ART§ 42 (60.9%) 278 (58.0%) 394 (63.6%) 714 (61.1%)
Follow up time in days, median (IQR) 333 (134–840) 755 (349–1207) 750.5 (320.5–1193) 733.5 (314.5–1182.5)
Outcome on study termination:
Alive and in active follow up 40 (58.0%) 361 (75.4%) 448 (72.3%) 849 (72.7%)
Dead 15 (21.7%) 37 (7.7%) 53 (8.6%) 105 (9.0%)
Lost to follow up* 8 (11.6%) 42 (8.8%) 63 (10.2%) 113 (9.7%)
transferred 6 (8.7%) 39 (8.1%) 56 (9.0%) 101 (8.6%)
WHO: World Health Organization; CDC: Centre for Disease Control; IQR: inter-quartile range; ART: anti-retroviral treatment
last contact with clinic > 3 months
§32 patients switched to second line therapy during the study period
CD4 count and %: measured within 120 days after date of registration or HIV status confirmationBMC Pediatrics 2009, 9:54 http://www.biomedcentral.com/1471-2431/9/54
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follow up time from start of ART in the first 3 months,
from 3–6 months and from 6 months onwards, and com-
pares these with the rates in children who never received
ART measuring follow up time from enrolment.
Overall mortality rate was four times higher among chil-
dren never started on ART than among children started on
ART (incidence rate ratio = 11.1/2.7 = 4.1; 95%CI:2.7–6.2;
P < 0.001).
ART eligibility of patients with early death
In order to investigate whether the early deaths among
patients not treated could have been prevented by earlier
treatment, we looked at whether patients had met the ART
eligibility criteria before death and the time between eligi-
bility and death. Out of 52 children not on ART who died
within 6 months after enrolment, 41 (79%) had fulfilled
the ART eligibility criteria at some point of time. Fourteen
(27%) of them died within 0–30 days after eligibility cri-
teria were met, 13 (25%) between 31–60 days, 5 (10%)
between 61–90 days, and 9 (17%) after 90 days.
Fourteen children (13% of all deaths) died within the first
month after admission and prior to ART initiation.
Median age was 49 months (IQR: 27–78).
Children lost to follow-up prior to ART initiation
Among 454 children who never started ART, 100 (22%)
children were lost-to-follow-up within the first six months
after registration, of whom 26 only came for one consul-
tation. As there was no active tracing of these patients,
eventual deaths occurring at home could not be ascer-
tained. Baseline characteristics of the children lost-to-fol-
low-up were: median CD4 count 402 (IQR: 22–664) and
CD4% 18.3 (IQR: 4.1–23.6) (for children ≥ 60 and <60
months respectively), 45 had W/A z-score <-3, 73 lived
outside the province, 93 were aged 18 months or above,
and 72 were registered before 2006.
Cohort outcomes of children who did and did not start ART  after enrollment in HIV programs Figure 1
Cohort outcomes of children who did and did not 
start ART after enrollment in HIV programs. Very 
early deaths – deaths within 3 months of enrollment.
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Outcomes of HIV-positive children 1 year after enrolment in program Figure 2
Outcomes of HIV-positive children 1 year after enrolment in program. ART: anti-retroviral therapy.
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Cause of early death
Contributing causes of very early death were assigned for
all children not started on ART and for 16/20 children on
ART. Among children not receiving ART, the most com-
mon illnesses contributing to death were tuberculosis (15
children, 41%), lower respiratory tract infections (9 chil-
dren, 24%), diarrhea (4, 11%) and wasting syndrome/
severe malnutrition (4 children, 11%). Among children
on ART, tuberculosis was the most common illness (7
children, 44%) and respiratory tract infections (4 chil-
dren, 25%).
Discussion
In this study looking at in-program mortality in a large
cohort of HIV-positive children enrolled in hospital-based
HIV programs in two provinces of Cambodia, we found
that although on-ART mortality was low, the pre-treat-
ment mortality and losses to follow-up were unacceptably
high. More than 6 out of every 10 deaths and almost 9 out
of every 10 children lost to follow up occurring after
enrollment in the HIV/AIDS programs happened among
children not yet started on ART. Loss to follow up was sig-
nificantly higher among non-treated children than among
children on antiretroviral treatment. We suspect that
many of the children lost-to-follow-up eventually died
and it is likely that all these deaths were not accounted for
in this group of patients. Mortality was, therefore, possi-
bly underestimated due to misclassification of unascer-
tained patient deaths as lost-to-follow-up.
Interestingly, among patients not started on ART, we
found that there were 73/100 cases LTFU who lived out-
side the province and 161/354 (45.5%) cases not LTFU
who lived outside the province (OR 3.2; 95%CI: 1.96–
5.36); P < 0.001). Age and sex were not associated with
LTFU (data not shown). This suggests that longer travel-
ling distances made access to care more difficult to the
point that children stopped coming back for consultation.
Despite the higher mortality rate for children not started
on ART recorded in our program, the mortality rate was
much lower than that for HIV-infected children measured
among Zambian children prior to availability of ART [9].
Such large difference may reflect the positive impact of
non-ART HIV care like cotrimoxazole prophylaxis, which
was universally implemented in our setting, and aggres-
sive treatment of opportunistic infections [10].
Mortality among children on treatment in our program
was low and comparable to other settings of high HIV
prevalence [1]. Moreover, the very low dropout rate (2%)
among children on ART suggested they were better fol-
lowed-up than those not on ART. This was a likely conse-
quence of the "active" tracing system, which was
unfortunately reserved for children on ART because these
activities, including home visits and social support, were
resource-demanding and beyond the program capacity.
There are various factors that can explain the relatively low
on-treatment mortality observed in our setting, even
though a third of children were severely immunosup-
pressed on admission. The low number of infants in the
cohort suggests that our in-program mortality reflects the
mortality among children who survived the first year of
life. Yet, it is known that most HIV deaths in children
occur during this crucial time [4,5]. In our program the
death ratio was highest in the youngest age group (<18
months). This could be partly explained by the fact that in
the absence of good coverage of early diagnosis, sympto-
matic infants were more likely to be identified in the pro-
gram than non-symptomatic ones. Although we could not
retrieve individual patient information on cotrimoxazole
and fluconazole prophylaxis, the systematic use of proph-
ylaxis was recommended throughout the program, and
would have contributed positively to limiting the mortal-
ity. Deaths occurring within one month of admission and,
to a certain extent, the early deaths occurring within three
months of admission are likely to reflect the late arrival of
children with advanced HIV/AIDS disease.
TB prevalence is high in Cambodia at 665 per 100 000
persons per year [11] and it is the most common oppor-
tunistic infection among HIV patients in the country. In
Table 2: Mortality in HIV-positive children (on ART and never on ART) enrolled in the HIV programs.
Person-time on ART (from ART initiation) Person-time never on ART (from admission)
Time period Deaths Person-years Rate per 100 PY (95%CI) Deaths Person-years Rate per 100 PY (95%CI)
< 90 days 20 168 11.9 (7.7–18.4) 37 92 40.0 (29.0–55.2)
90–180 days 7 322 2.2 (1.0–4.5) 15 170 8.8 (5.3–14.7)
> 180 days 12 1443 0.8 (0.5–1.5) 14 596 2.3 (1.4–4.0)BMC Pediatrics 2009, 9:54 http://www.biomedcentral.com/1471-2431/9/54
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this study, TB was the most common cause of death, in
nearly half of patients whether on ART or not. The chal-
lenges of diagnosing TB among HIV-positive children may
have contributed to this problem. Prevention, screening,
and treatment need to be optimized in order to reduce TB
related mortality. Moreover, the lack of clear recommen-
dations on the optimal time for starting ART during TB
treatment in children and the fear of paradoxical reactions
have likely contributed to clinicians delaying ART initia-
tion in children with active TB. The decision to start ART
during TB treatment is essentially a clinical judgment by
the physician [12].
Most of the children who died before starting treatment
had met the ART eligibility criteria (41/46), and could
thus have started ART before the time of death. Overall,
the average time to initiate ART (median of 4.7 months)
in the program was relatively long, although comparable
to community-based HIV programs in South Africa [13].
Some reasons for the delay in starting ART in our setting
included lack of experience of clinicians in the early years
of the program and the unnecessary requirement for two
CD4 values below threshold before ART initiation. Addi-
tionally, the time intervals between CD4 measurements
were long and there was no systematic recall of children
with low CD4 counts as children only came on their
scheduled appointment. Finally, delays in the identifica-
tion and training of a caregiver, especially if child was
orphan, were observed.
From our experience we were able to identify three catego-
ries of reasons for delays in treatment initiation: first,
delays in confirming HIV infection and enrolment in the
HIV/AIDS care program for HIV-exposed and infected
children (A & B in Figure 3); second, delays in establishing
the degree of HIV immunodeficiency using CD4 measure-
ments (C in Figure 3); and third, delays in initiating ART
after ART eligibility criteria (clinical and/or immunologi-
cal) were met (D).
Measures that contribute to minimizing these delays are
urgently needed to help reduce the pre-treatment mortal-
ity and, possibly, the high loss-to-follow-up rates. Meas-
ures to speed up admission to the HIV clinic include early
diagnosis and an efficient referral process. This implies the
scale-up of HIV testing among infants and young chil-
dren, in all out-patient services and in hospital wards, sys-
tematic HIV screening of children diagnosed with TB and
overall an efficient prevention of mother-to-child-trans-
mission program. Systematic DNA PCR testing in new-
borns is becoming increasingly available and would
promote early HIV diagnosis and referrals for ART.
Delays in initiating ART after enrolment to the program
could be minimized by the following:
1. Preparatory ART sessions could be scheduled as soon as
the diagnosis of HIV infection is made and before ART eli-
gibility criteria are met.
2. Access to CD4 measurements needs to be improved and
CD4 monitoring optimized to facilitate timely initiation
of ART: more frequent serial CD4 counts, and rapid feed-
back of results from laboratory. Should there be delays in
CD4 measurements, clinical criteria for presumptive diag-
nosis of severe HIV disease should be used to initiate ART
[8], while for infants, ART should be initiated regardless
CD4 count [14,15].
3. A fast-track channel for children first admitted with
advanced disease should be set-up: as soon ART eligibility
is established, prompt recall of patient should be made
without waiting for their next scheduled appointment.
4. If resources are available, a tracing system that is inclu-
sive of all children (not just those on ART) missing a clinic
appointment could help reduce loss-to-follow-up prior to
ART initiation.
Delays and deaths in pediatric HIV/AIDS care Figure 3
Delays and deaths in pediatric HIV/AIDS care.
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Strengths of this study include the large number of
patients and the fact that data came from a program set-
ting, thereby reflecting the operational reality on the
ground.
However, there are certain limitations to the study. First,
not all causes of death were reliably ascertained. Neverthe-
less, the level of error in attributing the cause of death was
limited, as both HIV-programs were situated within a pro-
vincial referral hospital and medical doctors performed all
consultations. Second, the not-treated patient group had
a higher lost to follow-up rate than the on-treatment
patient group (22% versus 1.8%) so there were likely
more unreported deaths in the not-treated group. Conse-
quently, the mortality rate ratio between the two groups
would be underestimated.
The relatively low mortality observed among children on
ART in these two pediatric treatment programs suggests
that these programs are providing effective care. However,
high in-program deaths and losses-to-follow-up prior to
ART initiation highlights the fact that relying solely on
ART outcomes as an indictor to assess program effective-
ness provides a distorted view of the overall performance
of pediatric HIV-care. Finally, we were not able to system-
atically document reasons for delaying treatment. Our
findings warrant a separate investigation on specific rea-
sons for ART delay including multivariate analysis of
parameters associated with non-treatment.
Conclusion
This study has shown that the measurement of in-pro-
gram mortality helps reveal obstacles in the provision of
care to HIV-positive children. It highlights challenges that
remain to be tackled in order to further optimize the care
for these children. Further studies should be done to look
at effective ways of reducing the delay to ART initiation
after meeting ART criteria and also whether less stringent
criteria for starting ART would lead to better outcomes.
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